Caroline Robert Journalist Profile

Articles

A plain language summary of the 7-year update from part 1 of the COLUMBUS study: encorafenib and binimetinib for people with BRAF V600-mutant melanoma

Jan 14, 2025 | tandfonline.com | Dirk Schadendorf |Reinhard Dummer |Keith T Flaherty |Caroline Robert

Plain Language SummaryWhat is this summary about? This summary presents the 7-year study results from COLUMBUS part 1, which tested encorafenib (BRAFTOVI®) and binimetinib (MEKTOVI®) combined (COMBO group) against encorafenib alone (ENCO group) or vemurafenib (ZELBORAF®) alone (VEMU group) as a treatment for a skin cancer called locally advanced or metastatic BRAF V600-mutant melanoma. What were the results?
Fiera Capital Appoints Klaus Schuster as Executive Director and Chief Executive Officer, EMEA

May 25, 2023 | ca.fierarealestate.com | Caroline Robert

Home Press Releases Fiera Capital Appoints Klaus Schuster as Executive Director and Chief Executive Officer, EMEA

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.